Sequoia China Capital and Highlight Capital co-led the GNI Group-backed cancer drug developer's series A round.
Cullgen, the US-based drug discovery platform developer backed by life sciences research and development firm GNI Group, has landed $16m in series A funding.
The round was co-led by venture capital firm Sequoia China Capital and investment firm Highlight Capital and it came after the company had received up to $15m in seed funding from GNI in March 2018.
Cullgen is has created a drug discovery platform that identifies and destroys disease-causing proteins by stimulating the body’s ubiquitin proteasome…
